SHIFT AI Newsroom · GLOBAL
Semaglutide May Aid Weight Loss and Reduce Inflammation in Adults with Overweight or Obesity
A systematic review and meta-analysis explores the effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults without diabetes
A systematic review and meta-analysis published on Europe PMC explores the effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. The study suggests that subcutaneous semaglutide may be effective in promoting weight loss and reducing inflammatory markers in this population.
What this means in the UK
This research is relevant to the UK as it may inform future treatment options for adults with overweight or obesity, a significant public health concern in the UK
Known facts
- Subcutaneous semaglutide may aid weight loss and reduce inflammatory markers in adults with overweight or obesity without diabetes